Resources

This report summarizes the proceedings from an international meeting organized by PATH and partners and held in Bangkok, Thailand, from September 3 to 4, 2025 for manufacturers and regulatory testing laboratories on polio vaccine quality control assays. Presenters provided updates on evolving guidance for the implementation of quality control assays for polio vaccines. This included the dissemination of results from a recent World Health Organization (WHO) collaborative study supporting the replacement of animal models with high-throughput sequencing for routine vaccine lot release. Other topics included the latest WHO collaborative study results on the suitability of the Sabin inactivated polio vaccine International Standard for in vivo rat potency testing; the availability of WHO universal reagents for polio vaccine potency assays; and the importance of harmonizing in-house assay standards and reagents with international standards and the WHO guidance. Finally, presenters discussed the potential of next-generation products, such as S19 virus-based IPV, that can be developed currently without biocontainment requirements.

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.To share any updates or corrections to the snapshot, please contact rsvsnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.To share any updates or corrections to the tracker, please contact rsvsnapshot@path.org.

The integration of artificial intelligence (AI) technologies into clinical practice stands as a defining challenge and opportunity for global health in the coming decade. While use cases such as clinical documentation and diagnostic support are becoming increasingly common in high-resource settings, where over half of clinicians now report using AI tools, much less is known about frontline clinicians’ experiences, barriers, and real-world needs in low- and middle-income countries (LMICs).In LMIC contexts, large language model (LLM)-enabled clinical decision support systems (CDSSs) offer the potential to extend high-quality decision support to settings with limited human and technical resources. Yet they also carry significant risks, including language bias, inequitable access, limited local capacity for oversight, and the possibility of recommendations that are misaligned with local medical guidelines that undermine patient safety or trust.Over the past two years, rapid advances in generative AI have outpaced the establishment of evidence, governance, and capacity frameworks required for responsible use. Health systems and policymakers are now faced with urgent questions:How can AI tools be evaluated for clinical safety and contextual relevance?What data infrastructures and regulatory mechanisms are needed for equitable deployment?And how can local researchers and health institutions lead, not just participate, in AI innovation?These questions form the basis of this CDSS Learning Agenda, which aims to generate collective insight and actionable evidence to guide safe, effective, and equitable integration of AI into health systems. The agenda identifies six thematic priorities—localization and language equity; evaluation and real-world evidence; voice-enabled and multimodal tools; capacity and local ownership; governance and trust; and infrastructure and enabling environments—that collectively define the ecosystem required for sustainable AI adoption in LMICs.

Through the Gavi-funded MICs Technical Assistance project, PATH partnered with governments and civil society in Indonesia, Ukraine, and Vietnam to strengthen immunization systems and address pandemic and conflict-related barriers to vaccination. PATH conducted rapid assessments, developed tools for microplanning and budgeting, and built capacity among local partners to identify zero-dose and underimmunized children, improve coordination, and promote equitable access to vaccinations. The tools and materials developed during the project are available to governments and civil society partners in any country looking to improve their vaccine coverage rates, engage local partners, or strengthen their immunization planning and budgeting.